Please login to the form below

Not currently logged in


This page shows the latest cobimetinib news and features for those working in and with pharma, biotech and healthcare.

Another IO knockback as Tecentriq combo fails phase III trial

Another IO knockback as Tecentriq combo fails phase III trial

The IMblaze370 trial of PD-L1 inhibitor Tecentriq (atezolizumab) and MEK inhibitor Cotellic (cobimetinib) as a third-line treatment option in people with difficult-to-treat, locally advanced or metastatic colorectal

Latest news

More from news
Approximately 5 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....